ArQule sees positive data from trial of lung cancer drug

03/31/2010 | Reuters

ArQule's lung cancer drug ARQ 197 helped improve progression-free survival by 66% in patients with advanced, refractory nonsmall-cell lung cancer when combined with a similar treatment, erlotinib. The result puts ArQule on track to move on with late-stage development.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID